Data as of Dec 19
| +0.05 / +2.87%|
The 3 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +67.60% increase from the last price of 1.79.
The current consensus among 3 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.